Table: Nxera Pharma -9-MTH group results (IFRS)

Nxera Pharma

31/10/2025 06:33

Oct 31 (Reuters)- 
              Nxera Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   9 months ended      9 months ended       Year to 
                  Sep 30, 2025        Sep 30, 2024     Dec 31, 2025 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales               21.85               21.98                     
                   (-0.6 pct)         (+301.6 pct)                  
  Operating         loss 5.91           loss 2.85                   
  Pretax            loss 6.84           loss 2.29                   
  Net               loss 4.81           loss 3.50                   
  EPS Basic      loss 53.31 yen      loss 39.06 yen                 
  EPS Diluted    loss 53.31 yen      loss 39.06 yen                 
  Ann Div                                  NIL              NIL     
  -Q2 Div              NIL                 NIL                      
  -Q4 Div                                  NIL              NIL     
 
  NOTE - Nxera Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4565.T